venetoclax
venetoclax: developed by 1 company · 158 clinical trials tracked · 1 FDA decision.
venetoclax evidence translation
What we can confirm
1 FDA record · 158 tracked trials
What it means
What to watch
Prepared research question
How could venetoclax → ABBV affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 32 study sponsors
Related indications
Development Pipeline (1)
| Company | Phase |
|---|---|
| AbbVie Inc. (ABBV) Acute Myeloid Leukemia (AML); Diffuse Large B-cell Lymphoma;… | Phase 4 |
Clinical Trials (158)showing 10 most recent
Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations
Primary endpoint: Rate of Participants Achieving Complete Remission (CR) with Undetectable Minimal Residual Disease (uMRD) in Bone Marrow
A Phase 1b Dose Escalation and Dose Expansion Study of CLN 049 in Combination With Azacitidine and Venetoclax for the Treatment of Adult Patients With Newly Diagnosed, Acute Myeloid Leukemia
Primary endpoint: Incidence and severity of adverse events (AEs)/adverse events of special interest (AESIs)/serious adverse events (SAEs) [safety and tolerability] of CLN-049 combined with azacitidine and venetoclax
A Phase Two Study of Venetoclax Plus Zanubrutinib in Newly Diagnosed CLL and After Front-Line Time-Limited Venetoclax-Based Therapy
Primary endpoint: Rate of undetectable minimal residual disease (uMRD) (Firstline Cohort)
A Phase 2 Study of Nemtabrutinib and Venetoclax as Frontline Treatment for Chronic Lymphocytic Leukemia (CLL)
Primary endpoint: Presence of undetectable minimal residual disease (MRD)
An Open-label, Multicenter Phase 1b/2 Study to Evaluate the Safety and Efficacy of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
Primary endpoint: Number of participants with treatment-emergent adverse events
Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated/Deleted AML Patients
Primary endpoint: Phase 2 Dose Level determination
A Two Cohort, Randomized, Double-Blind, Placebo-Controlled, Phase II Multi-Center Signal-Finding Study of Venetoclax Combined With Reduced-Intensity Conditioning Followed by Allogeneic Hematopoietic Cell Transplantation Then Venetoclax Maintenance in Adult Patients With Acute Myeloid Leukemia in First Complete Remission: A MyeloMATCH Sub-Study
Primary endpoint: Event free survival (EFS)
A Randomized Phase 2/3 Study Evaluating the Safety and Efficacy of Pivekimab Sunirine (PVEK) in Combination With Venetoclax and Azacitidine in Adult Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) Ineligible to Receive Intensive Chemotherapy
Primary endpoint: Phase 2: Complete remission (CR)
Immune-targeted Combination With Acute Lymphoblastic Leukemia-like Chemotherapy for Adult of Acute Leukemia of Ambiguous Lineage: A Prospective, Single-arm, Multicenter Clinical Study
Primary endpoint: overall survival (OS)
The MAVRiC Study: A Phase II Study of Disease Risk Mutation Guided Finite Duration Acalabrutinib Plus Venetoclax for Relapse in CLL/SLL After First-line Finite Covalent BTKi Plus BCL2i Combination, With or Without Obinutuzumab
Primary endpoint: Overall Response Rate (ORR)
FDA Decisions1 records
Frequently asked questions
Who is developing venetoclax?
venetoclax is being developed by AbbVie Inc..
How many clinical trials involve venetoclax?
BioSniper tracks 158 clinical trials involving venetoclax.
What is venetoclax's latest FDA decision?
The most recent tracked FDA decision for venetoclax is Approval, dated April 11, 2016.